NASDAQ · Biotechnology
IONS (IONS) Stock
$54.37
-2.84%
NASDAQ: IONS
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Why Arrowhead Shot Sky-High, While Chief Rival Ionis Toppled
Investor's Business Daily · Jul 22, 2026
Earnings Preview: Ionis Pharmaceuticals (IONS) Q2 Earnings Expected to Decline
Zacks · Jul 22, 2026
Cathie Wood Just Bet Big on This Biotech Stock
Motley Fool · Jul 18, 2026
Ionis to hold second quarter 2026 financial results webcast
Business Wire · Jul 15, 2026
Biogen Slumps As Alzheimer's Study Leaves 'More Questions Than Answers'
Investor's Business Daily · Jul 14, 2026
Cash Flow (USD)
Valuation & Return Ratios
Peer Comparison
About IONS
IONS is led by CEO Brett Monia, employs 1,402 people, headquartered in Carlsbad, US, publicly traded since 1991.
IONS stock trades at $54.37 with a market capitalization of $8.99B. The stock is valued at a price-to-earnings (P/E) ratio of -41.80, price-to-book of 27.91, price-to-sales of 12.99. Over the past 52 weeks the stock has ranged between $40.03 and $86.74, and currently trades 37.3% below its 52-week high.
On profitability, IONS generates a return on equity (ROE) of -58.57%, return on capital employed of -12.91%, an operating margin of -33.35%, a net profit margin of -30.87%.